Zyngenia, Inc. Raises $10 Million in Series A Funding

- Next-Generation Biotherapeutics Company Appoints Board of Directors,
Management Team -

ROCKVILLE, Md., Nov. 4 /PRNewswire/ -- Zyngenia, Inc., a privately held
biotherapeutics company focused on next-generation antibody drug development,
today announced that it has secured $10 million in Series A funding from New
Enterprise Associates (NEA), one of the world's leading venture capital firms.
The capital will be used to create novel, multi-specific antibody-like
molecules that address two or more biological targets with a single agent. The
company will initially focus on various cancers and autoimmune diseases.

"Zyngenia's technology platform, developed by Carlos Barbas of The Scripps
Institute, is very compelling due to its ability to create biologics that are
single protein-combination therapeutics in a manner that is likely to be
scientifically, medically, and economically transforming," said Peter Kiener,
D.Phil., Zyngenia Chief Executive Officer. "With financial support from NEA,
we are poised to take a leadership role in the development of multi-specific
biologic therapies."

In previous positions at MedImmune and Bristol-Myers Squibb (BMS), Dr. Kiener
gained extensive experience in both biologics and small molecule drug
discovery across oncology, immunology, infectious disease and other
therapeutic areas. During eight years at MedImmune, most recently as Executive
Vice President and Head of Research and Development, Dr. Kiener helped to
build industry-leading protein and antibody engineering capabilities and
oversaw the submission of numerous INDs and BLAs. Dr. Kiener was also
responsible for the integration of both the protein/antibody engineering
company Cambridge Antibody Technology and the B-cell biologics company
Cellective Therapeutics into MedImmune. Prior to joining MedImmune, Dr.
Kiener spent 18 years with Bristol-Myers Squibb's Pharmaceutical Research
Division.

Carlos F. Barbas, III, Ph.D., Zyngenia's Chief Scientific Officer, is
Professor and Chair of the Skaggs Institute of Chemical Biology and the
Departments of Molecular Biology and Chemistry at The Scripps Institute, La
Jolla, California. Dr. Barbas is renowned for his work in peptides and
proteins, antibodies and chemically programmed antibodies. He has particular
expertise in novel antibody technologies and was a founder of two successful
antibody platform companies, Cov-X Pharmaceuticals (acquired by Pfizer) and
Prolifaron (acquired by Alexion).

Zyngenia's founding management team also includes Joseph Amprey, M.D., Ph.D.,
former head of MedImmune Ventures, Inc., as Chief Business Officer. Dr. Amprey
joined MedImmune Ventures as the first full-time employee and helped grow the
portfolio from 13 investments to 28. He led 11 deals during his time at
MedImmune Ventures and served on five boards. Recently, David Hilbert, Ph.D.,
has been appointed the Vice President and Head of Research and Development.
Dr. Hilbert formerly served as Vice President of Research at both Cellective
Therapeutics and Human Genome Sciences. Dr Hilbert led Research and
Development at Cellective until its acquisition by MedImmune in 2005. At Human
Genome Sciences, Dr Hilbert led the transformation of the company from a
genomics research company to an integrated drug development organization. His
expertise in oncology, autoimmunity and antibody development enabled the first
IND for the company and was pivotal in the development of ABthrax and
Benlysta.

In conjunction with the Series A financing, David M. Mott, NEA General
Partner, will become Chairman of the Board. Robert Garland, M.D., Partner at
NEA, will also join the company's board of directors. Mr. Mott focuses on
biopharmaceutical investments at NEA. He is Chairman of 3-V Biosciences, a
Director of Ardelyx and Zosano Pharma, and serves on the advisory board of the
Scripps Translational Science Institute. Prior to joining NEA, he was
President and CEO of MedImmune, which was acquired by AstraZeneca for $15.6
billion in 2007. During his 16 years at MedImmune, it grew from a small
biotechnology company into one of the five largest biotechnology companies in
the world. Dr. Garland focuses on biopharmaceutical investments at NEA and is
a Director of 3-V Biosciences, Cardioxyl Pharmaceuticals and Trevena, Inc. He
trained in Internal Medicine and Infectious Diseases at the University of
California, San Francisco. Prior to NEA, in addition to clinical practice at
UCSF, Dr. Garland was with McKinsey & Company where he worked with
biotechnology, pharmaceutical, medical device and diagnostics clients to
evaluate investments, formulate product and corporate strategies and build
businesses.

"We believe the unique Zyngenia platform has the potential to produce numerous
therapeutic proteins, each with specificity for multiple targets, which may
have significant advantages over both current single-specificity and
bi-specific biologic drugs," said Mr. Mott. "We are excited about combining
the therapeutic potential of this technology with a management team that has
an impressive record of successfully building companies and developing
biologics."

"It's rewarding to see my scientific technology platform coupled with the
capabilities of Zyngenia's management team," said Dr. Barbas. "I look forward
to working closely with the team and to leveraging the experience in biologic
drug development and corporate strategy that Mr. Mott and Dr. Garland bring as
we build the organization."

About Zyngenia, Inc.
Founded in 2008, Zyngenia, Inc. is a privately held biotherapeutics company
focused on the development of next-generation multi-specific antibodies. The
company uses proprietary patented technology to engineer single molecular
entities that may interact with two or more targets. The company will
initially focus its Zybody(TM) development on therapies for various cancers
and autoimmune disorders. Zyngenia is headquartered in Rockville, Maryland.
For more information, visit www.zyngenia.com.

About New Enterprise Associates
New Enterprise Associates, Inc. (NEA) is a leading venture capital firm
focused on helping entrepreneurs create and build major new enterprises that
use technology to improve the way we live, work and play. Since its founding
in 1978, the firm has followed the same core principles: supporting its
entrepreneurs, providing an excellent return to its limited partners and
practicing its profession with the highest standards and respect. Through its
affiliated funds, NEA focuses on investments at all stages of a company's
development, from seed stage through IPO. With approximately $8.5 billion in
committed capital, NEA's experienced management team has invested in over 650
companies, of which more than 165 have gone public and more than 255 have been
acquired. NEA has U.S. offices in Chevy Chase, Maryland; Menlo Park,
California; and Baltimore, Maryland. In addition, New Enterprise Associates
(India) Pvt. Ltd. has offices in Bangalore and Mumbai, India and New
Enterprise Associates (Beijing), Ltd. has offices in Beijing and Shanghai,
China. For additional information, visit www.nea.com.

SOURCE Zyngenia, Inc.

Jamie Lacey-Moreira of PressComm PR, LLC, +1-443-212-5260,
jamielacey@presscommpr.com